PLoS ONE (Jan 2022)

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy

  • Kenta Takaura,
  • Masayuki Kurosaki,
  • Kento Inada,
  • Sakura Kirino,
  • Kouji Yamashita,
  • Tomohiro Muto,
  • Leona Osawa,
  • Shuhei Sekiguchi,
  • Yuka Hayakawa,
  • Mayu Higuchi,
  • Shun Kaneko,
  • Chiaki Maeyashiki,
  • Nobuharu Tamaki,
  • Yutaka Yasui,
  • Jun Itakura,
  • Kaoru Tsuchiya,
  • Hiroyuki Nakanishi,
  • Yuka Takahashi,
  • Namiki Izumi

Journal volume & issue
Vol. 17, no. 2

Abstract

Read online

Background and aim The long-term prognosis of hepatocellular carcinoma (HCC) treated at a very-early-stage (the Barcelona Clinical Liver Cancer (BCLC) classification stage 0) was unclear, especially in terms of background liver disease. Methods This single-center, retrospective study included 302 patients with BCLC stage 0 HCC treated with radiofrequency ablation (RFA) and followed for at least six months. We examined the impact of background liver disease on overall survival and recurrence. Results The median age was 72 (range; 36–91) years; the median tumor diameter was 15 (range; 8–20) mm. The etiologies of background liver disease were hepatitis B virus infection (HBV) in 24 cases, hepatitis C virus infection (HCV) in 195 cases, and non-viral (NBNC) in 83 cases. Among the patients with HCV, 63 had achieved sustained virological response (SVR) by antiviral therapy (HCV SVR) before developing HCC (n = 37) or after HCC treatment (n = 26), and 132 had active HCV infection (HCV non-SVR). The median overall survival was 85 (95% CI; 72–98) months, and the median recurrence-free survival was 26 (95% CI; 20–30) months. Active infection with hepatitis C virus negatively contributed to overall survival (HR 2.91, 95% CI 1.31–3.60, p = 0.003) and recurrence-free survival (HR 1.47, 95% CI 1.06–2.05, p = 0.011). Conclusions The prognosis of RFA treatment for very early-stage HCC was favorable. Achieving SVR in hepatitis C was important for further prognosis improvement.